2nd Annual Cell and Gene Therapy Manufacturing – Agenda

Day 1: 3 November 2020


Joint Opening Plenary


13:00
Opening Address:
China’s Big Leap towards BioPharma 2030 – Innovation, Industrialization, Internationalization

Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

13:30
Keynote Address:
China’s Biopharma Capital Markets – Future Funds and Innovative Financing

Fu Wei, Chief Executive Officer, CBC Group, China

14:00
Online Networking & Stretch Break

14:15
Venture Capitals’ Roundtable:  
Show Me the Drug

  • Investment landscape in the Chinese biopharma market
  • Evaluating drug pipelines and development prospects
  • Mergers, expansion and JVs – Where do we see transactions picking up?
  • Financing new plants, new therapeutics, product launch and scaling-up operations – How do we review?
  • Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?

Moderator:
Fu Wei, Chief Executive Officer, CBC Group, China

Panelists:
Rani Jarkas, Chairman, Cedrus Group, Hong Kong
Judith Li, Partner, Lilly Asia Ventures, China
Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, China
Lynn Yang, Managing Director, Sequoia Capital, China

14:55
INDUSTRY SPOTLIGHT:
Enhancing Complex Protein Expression with Highly Efficient Gene Integration Technology

Dr. Allison Porter, Head of Expression System Sciences, Lonza Pharma & Biotech, U.K.

15:25
Online Networking & Stretch Break


End of Joint Opening Plenary and 2nd Cell & Gene Therapy Manufacturing commences

China Market


15:40
Chairperson’s Opening Remarks

15:40
Case Study: Tumor-infiltrating Lymphocyte Development

  • Development of potential candidates
  • Managing China’s cell therapy landscape

Liu Yarong, Chief Executive Officer, Grit Therapeutics, China

16:10
The Case of Solid Tumors:
From Liquid to Solid Tumors, from Manual to Automatic Manufacturing

  • Product differentiation: solid tumor advantages
  • Overcoming challenges of targeting solid tumors

Dr Zhang Yu, Senior Vice President and Chief Scientific Officer, Vcanbio Cell&Gene Engineering, China

16:40
Chairperson’s Summary and End of Day 1

Day 2: 4 November 2020

13:00
Chairperson’s Opening Remarks

Shaheer Bardissi, Executive Board Member, Head of Gene and Cell Therapy, Minapharm Pharmaceuticals, Egypt


Technology and Innovation


13:00
Cell and Gene R&D Strategy Showcase – A Case Study of Epigeneron

  • Therapeutic target discovery programs and the molecular diagnostics programs
  • Scientific and commercial breakthroughs of therapies
  • Japan’s cell and gene therapy market in glance

Hara Ryujiro, Head of R&D Strategy, Epigeneron, Inc, Japan

13:30
Technical Showcase: Treating Solid Tumors with TCR-T Therapy

  • Generation of TCR T11.8-10-17 by HLA-A*02 allogenic priming approach
  • Tumor cell recognition assay for efficacy safety
  • Parallel studies using retroviral and lentiviral SIN systems

Liu Jingxian, TCR Discovery and Early Development, Cytovant Sciences, China

14:00
Online Networking and Stretch Break

14:30
Allogeneic Mesenchymal Stromal Cells Product Stempeucel® – approved for manufacturing & marketing in India for Critical Limb Ischemia Management

Pawan Gupta, Vice President, Medical Affairs, Stempeutics, India

15:00
Accelerating CAR-T Development and Manufacturing

  • Understanding and assessing manufacturability
  • Addressing the cost problem and solutions
  • Chemistry, Manufacturing, and Controls (CMC) case study
  • Product enhancement, innovation and technology

Dr Yao Shuyuan, VP of Operations, Wuxi AppTec and General Manager, Wuxi ATU, China

15:30
Online Networking & Stretch Break

15:50
World’s First off-the-shelf NK Cell-based Immunotherapy in the Fight Against Cancer

Troels Jordansen, CEO, Glycostem Therapeutics, Netherland

16:20
Indonesia Case Study: Developing UC Stem Cells for COVID-19

  • Challenges in supply chain management
  • Working with small group trials

Sandy Qlintang, Deputy Director, PT Kalbe, Indonesia

17:00
Chairperson’s Summary and End of Day 2

Day 3: 5 November 2020

13:00
Chairperson’s Opening Remarks


Investments and Commercialisation


13:00
Biotech Investors’ Roundtable: Financial Incentives, Investments and Pricing 

  • Pricing, investment and making the therapies affordable
  • Post COVID-19 investment climates
  • Commercial models
  • Market access, and reimbursement models

Moderator:
Rohit Kulkarni, Vice President, Stem Cell Society of India, India

Panelists:
Kan Chen, Principal, Qiming Weichuang Venture Capital Management, China
Paolo Morgese, Director for EU Market Access and Member Relations, Alliance for Regenerative Medicine, Switzerland

13:50
Commercialisation Models and Case Studies of CAR-Ts

  • Scenarios of EMA approvals and market access
  • Pricing mechanisms
  • European market outlook for treatment
  • CART-T and regenerative market commercial potential

Paolo Morgese, Director for EU Market Access and Member Relations, Alliance for Regenerative Medicine, Switzerland

14:30
Online Networking & Stretch Break

15:00
Assessing Stem Cells Market Opportunities – the Case of India

  • Challenges, opportunities and growth prospects
  • COVID-19 period approval process and challenges in clinical trials

Rohit Kulkarni, Vice President, Stem Cell Society of India, India

15:40
Introducing Advanced Therapies into Emerging Countries: A Case Study

  • Availability and affordability
  • Challenges associated to opportunities
  • An integrated model for innovation and affordability

Shaheer Bardissi, Executive Board Member, Head of Gene and Cell Therapy, Minapharm Pharmaceuticals, Egypt

16:15
Chairperson’s Summary and End of Day 3